Rectal indometacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients: a double-blind, randomised controlled trial
Authors:
- 1 February 2020
- journal article
- research article
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 5 (2) , 132-141
Abstract
No abstract availableKeywords
Funding Information
- American College of Gastroenterology
This publication has 37 references indexed in Scilit:
- A Randomized Trial of Rectal Indomethacin to Prevent Post-ERCP PancreatitisNew England Journal of Medicine, 2012
- Complications of ERCPGastrointestinal Endoscopy, 2012
- Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposalTrials, 2010
- Clinical Pharmacokinetics of DiclofenacClinical Pharmacokinetics, 1997
- Inhibition of serum phospholipase-A2in acute pancreatitis by pharmacological agentsin vitroScandinavian Journal of Clinical and Laboratory Investigation, 1997
- Major Hemorrhage from Endoscopic Sphincterotomy: Risk Factor AnalysisJournal of Clinical Gastroenterology, 1994
- Endoscopic sphincterotomy complications and their management: an attempt at consensusGastrointestinal Endoscopy, 1991
- ERCP- and Endoscopic Sphincterotomy-Induced PancreatitisPancreas, 1991
- Hyperamylasaemia and Acute Pancreatitis Following Endoscopic Retrograde CholangiopancreatographyPancreas, 1986
- Bioavailability of Indomethacin after Intramuscular Injection and Rectal Administration of Solution and SuppositoriesActa Pharmacologica et Toxicologica, 1985